Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14307075 | 0.86 | TSHR (0.42) | KMT2ATSHRGAAKDM4EL3MBTL1 | |
| SCHEMBL7830017 | 0.79 | MAPK1 (0.61) | TSHRGAAKDM4EHPGDMAPK1 | |
| SCHEMBL7834032 | 0.77 | SMN1; SMN2 (0.64) | KMT2ASMN1; SMN2TSHRGAAKDM4E | |
| SCHEMBL14231942 | 0.71 | SMN1; SMN2 (0.58) | KMT2ASMN1; SMN2KDM4EMEN1HTT | |
| SCHEMBL11840596 | 0.70 | CRHBP (0.48) | KMT2ATSHRGAAKDM4EL3MBTL1 | |
| SCHEMBL7830417 | 0.70 | L3MBTL1 (0.64) | KMT2ASMN1; SMN2TSHRKDM4EL3MBTL1 | |
| SCHEMBL11708542 | 0.68 | KMT2A (0.68) | KMT2ASMN1; SMN2GAAKDM4EL3MBTL1 | |
| SCHEMBL2248519 | 0.68 | KMT2A (0.52) | KMT2ASMN1; SMN2GAAKDM4EL3MBTL1 | |
| SCHEMBL4167785 | 0.68 | KDM4E (0.48) | KMT2ASMN1; SMN2TSHRGAAKDM4E | |
| SCHEMBL3571705 | 0.67 | KMT2A (0.51) | KMT2ASMN1; SMN2GAAKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100104644-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-04-29 | — | — | US | claimed |
| US-20090291919-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Light Toxicity | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-11-26 | — | — | US | claimed |
| US-20090286808-A1 | Opsin Stabilizing Compounds and Methods of Use | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-11-19 | — | — | US | claimed |
| EP-2069390-A2 | OPSIN STABILIZING COMPOUNDS AND METHODS OF USE | University of Florida Research Foundation, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| EP-2069391-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OPHTHALMIC DISEASE | University of Florida Research Foundation, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2008013984-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OPHTHALMIC DISEASE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-01-31 | — | — | WO | claimed |
| WO-2008013983-A2 | OPSIN STABILIZING COMPOUNDS AND METHODS OF USE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-01-31 | — | — | WO | claimed |
| US-20100104644-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100104644-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100104644-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20090291919-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Light Toxicity | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291919-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Light Toxicity | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291919-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Light Toxicity | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090286808-A1 | Opsin Stabilizing Compounds and Methods of Use | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| EP-2069390-A2 | OPSIN STABILIZING COMPOUNDS AND METHODS OF USE | University of Florida Research Foundation, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-2069391-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OPHTHALMIC DISEASE | University of Florida Research Foundation, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008013984-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OPHTHALMIC DISEASE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013984-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OPHTHALMIC DISEASE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013986-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OPHTHALMIC LIGHT TOXICITY | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013983-A2 | OPSIN STABILIZING COMPOUNDS AND METHODS OF USE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291919-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Light Toxicity | ALDH1A2, EYA3, PDE6C | KMT2A 4649/4885SMN1; SMN2 4664/4885TSHR 3309/4885 |
| US-20100104644-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Disease | ALDH1A2, PDE6C, EYA3 | KMT2A 4691/4885SMN1; SMN2 3321/4885TSHR 4547/4885 |
| US-20090286808-A1 | Opsin Stabilizing Compounds and Methods of Use | CRYZ, NR2E3, CRYAB | KMT2A 4623/4885SMN1; SMN2 231/4885TSHR 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.